BioSyent Signs Exclusive Agreement for New Women’s Health Product
01. Oktober 2020 09:25 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 01, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License...
BioSyent Releases Q2 and H1 2020 Results
26. August 2020 07:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30,...
BioSyent to Present at the LD 500 Virtual Conference
24. August 2020 16:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 24, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced that it will be presenting at the LD 500 investor conference on...
BioSyent Schedules Q2 and H1 2020 Earnings Release for August 26, 2020
17. August 2020 08:30 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...
BioSyent Announces the Availability of Tibella® (tibolone) in Canada
29. Juli 2020 16:01 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, July 29, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced the Canadian launch and product availability of Tibella® (tibolone)...
BioSyent Releases Results for Q1 2020
28. Mai 2020 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 28, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key...
BioSyent Schedules Q1 2020 Earnings Release For May 28, 2020
21. Mai 2020 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 21, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2020 on...
FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Fifth Consecutive Year
01. Mai 2020 09:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, May 01, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fifth consecutive year, FeraMAX® has been named the #1...
BIOSYENT ANNOUNCES GRANT OF RESTRICTED SHARE UNITS
31. März 2020 19:41 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 31, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved today a grant of 129,125...
BioSyent Releases Results for Fourth Quarter and Full Year 2019
18. März 2020 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 18, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December...